Mapping vulnerable cell types in Alzheimer's disease models
Multidimensional mapping of vulnerable cell types in humanized Alzheimer's disease mouse models
This study is looking at how certain brain cells react to the harmful effects of Alzheimer's disease, especially the buildup of specific proteins, to find out which cells are most affected and how we might help protect or heal them in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11078735 on NIH RePORTER |
What this research studies
This research investigates how different types of brain cells respond to the damaging effects of Alzheimer's disease, particularly focusing on the aggregation of amyloid-beta and tau proteins. By using advanced techniques like single-cell transcriptomics and novel mouse models that mimic human Alzheimer's, the researchers aim to identify specific cell types that are more vulnerable to these pathological changes. This could help in understanding the mechanisms behind the disease and potentially lead to targeted therapies. Patients may benefit from insights gained about how to protect or restore these vulnerable cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a family history of Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating Alzheimer's disease by targeting vulnerable brain cells.
How similar studies have performed: Previous research has shown promising results in understanding cell vulnerability in Alzheimer's, indicating that this multidimensional approach could yield significant insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Cobos, Inma — Stanford University
- Study coordinator: Cobos, Inma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.